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INTRODUCTION: The prognosis of patients with metastatic breast cancer is very poor. Because of this,
treatment of skeletal metastasis is often palliative with limited goals rather than cure. However, there
are those patients, such as presented here, who survive for an extended time.
PRESENTATIONOF CASE: This thirty-six year old female presentedwith lytic lesions to one ulna and rib ﬁve
years aftermastectomy for breast cancer. Despite radiation and chemotherapy, the ulnar lesion expanded
and resulted in an elbowdislocation. The rib lesionwas resected and the armamputated above the elbow.
She developed local recurrence in both her above elbow amputation stump and chest wall and a more
proximal below shoulder amputation was performed with resection of chest wall lesion. Even though
she had locally aggressive disease, she has survived for 31 years after diagnosis without any evidence of
disease.
DISCUSSION: Reports of metastatic breast cancer survival indicate the ﬁve year survival to be 15%. There
have been few reports indicating that those patients with skeletal only or oligometastatic disease have
improved prognosis. It is not clear what biological properties of these tumors results in the improved
survival.
CONCLUSION: This case highlights the challenges of giving patients the optimal treatment in the light of
limited ability to predict prognosis. It also highlights the need to further investigate the phenotypes of
breast cancer that can, despite metastatic disease and with modern treatment go on to long survival. In
addition this case demonstrates the importance of long term followup.
© 2014 The Authors. Published by Elsevier Ltd. on behalf of Surgical Associates Ltd. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
1. Introduction
The prognosis of patients with metastatic breast cancer is in
general very poor. The 5 year survival rate from the national can-
cer database has been reported to be 15% and the median survival
rate is 8–24 months [1]. Many of these patients will referred for
an orthopedic consultation because half of women who present
with metastatic breast cancer at primary diagnosis will develop
bone lesions [2]. Because of this the orthopedic treatment of skele-
tal metastasis for these patients is often palliative with the goal
being relief of pain and restoration of short term function, rather
than that of affecting a cure. However, there are those patients that
despite the poor odds against them are able to survive.
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2. Presentation of case
A thirty-six year old Caucasian female secretary presented to
the orthopedic clinic in 1988 with a 9 month history of a painful,
tender mass involving the midshaft of her left ulna. She reported
that the pain was constant, worse with activity and only partially
relieved by pain medication. She had a history of a modiﬁed left
mastectomy for carcinoma of her breast in 1983, 5 years earlier.
At that time she had two positive axillary lymph nodes which had
been removed. Besides her mastectomy she was treated with 1.5
years of chemotherapywith vincristine, adriamycin and cyclophos-
phamide. She received no pre or postoperative radiation.
On presentation to the orthopedic ofﬁce radiographs were
obtained of her left forearm which demonstrated an osteolytic
lesion involving 4 cm of the ulna. A chest X-ray, taken at the same
time, revealed a similar osteolytic lesion in the left sixth rib with
an associated pleural based mass. A true cut needle biopsy of the
forearm tumor revealed an adenocarcinoma compatible with the
diagnosis ofmetastatic breast carcinoma. Itwas decided at the time
that the likelihood of a cure was remote. The patient therefore,
received radiation treatment for each of these two skeletal lesions
http://dx.doi.org/10.1016/j.ijscr.2014.12.017
2210-2612/© 2014 The Authors. Published by Elsevier Ltd. on behalf of Surgical Associates Ltd. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).
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Fig. 1. (A) Lateral and (B) AP radiographs of the forearm demonstrating a large lytic lesion throughout the ulnar shaft caused by metastatic breast cancer.
Fig. 2. (A) Lateral and (B) AP radiographs of the forearm demonstrating advancement of the lytic lesion despite radiation treatment resulting in dislocation of the radial –
humeral articulation and signiﬁcant pain with loss of function.
and was placed on Nolvadex. The patient returned to the ofﬁce in
1992. She had signiﬁcant relief for a few years after the second
round of treatment but now the pain had returned in the forearm.
Radiographs at that time showed that the tumor had advanced to
destroymost of the ulna sparing only it’s proximal few centimeters
(Fig. 1) but the patient was feelingwell and no plansweremade for
any surgical intervention. However, over the next year the tumor
continued to advance destroying the entire ulna leading to disloca-
tion of the elbow (Fig. 2). She developed severe pain in her forearm
and signiﬁcant disability due to the lack of left arm function. At that
time she requested amputation of her arm.
To relieve symptoms and decrease the tumor burden a pallia-
tive above elbow amputation was performed in 1993. The mass
was 15×4×4 cm in size and resulted in destruction of the prox-
imal ulna, invasion of the distal humerus and dislocation of the
radius (Fig. 3). Recent histological analysis of retained specimens of
her tissue was performed which demonstrated that the tumor was
apocrine inmorphology, positive for Her2 nu, and androgen recep-
tor but negative for estrogen and progesterone (Fig. 4). In addition
to her amputation, segments of two ribs were removed where her
Fig. 3. H+E stained large mount sections of the proximal aspect of the forearm
amputation. These slides demonstrate the signiﬁcant size of the lesion and the
dislocation that occurred at the elbow due to the mass.
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Fig. 4. Histopathology and immunostains of the tumor from the amputated limb with H+E; (A and B) tumor involves the bone ((A) 2×, (B) 10×); (C) tumor involves
adipose tissue (10×), note the apocrinemorphology of the tumor with conspicuous eosinophilic granular cytoplasm (inset, 60×); (D) tumor involves the deep and superﬁcial
dermis and sparing the epidermis (2×); (E) Estrogen receptor negative (10×); (F) HER2 positive with strong and complete membranous staining compatible with 3+ (10×);
(G) GCDFP-15 positive staining (10×); (H) Androgen receptor positive (10×). The morphology and immunoproﬁle are compatible with HER2+ apocrine type mammary
carcinoma.
second and only other lesion was identiﬁed. She was treated with
vinblastine, doxorubicin, thiotepa, and halotestin (VATH) as well
as tamoxifen. Despite this treatment, three years after the ampu-
tation, she developed a recurrent mass in her above elbow stump.
A below shoulder amputation was performed in 1996 (Fig. 5). An
8×6×4 cm tumormass in the soft tissues to the anterior humerus
as demonstrated on histology. The bed of the rib resectionwas also
re-excised since she had developed a recurrence in her chest wall.
Novantrone, citovorin and 5 FU were added to her regimen for an
additional round of chemotherapy. After her surgery she was also
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Fig. 5. AP radiograph of the shoulder demonstrating the above elbow amputation.
Table 1
Timeline for clinical case.
1983 Mastectomy and 2 nodes removed age 31 years
1988 Diagnosed with skeletal metastasis to ulna and rib: radiation and
chemotherapy
1992 Above elbow amputation with rib resection
1996 Below shoulder revision amputation with revision rib resection
2014 No evidence of disease at age 62: patient reports that she is not
signiﬁcantly disabled years since radical mastectomy and 18 years
since last operation
placed on Arimidex. She had not returned to the clinic after her
chemotherapy and we had presumed that she had passed away.
Follow up on the patient 26 years after being ﬁrst seen with
metastases in her left ulna and 6th rib wewere pleased to ﬁnd that
she was doing exceptionally well (Table 1). It is now 31 years since
her left breast mastectomy and 18 years from her below shoulder
amputation and rib re – resection and she is now without recur-
rence. She is now 62 years old, and in good health. She wears a
cosmetic left arm and works in her original job as a secretary with
the aid of a computer and reports not to feel signiﬁcantly disabled.
3. Discussion
This case is one of only a limited number of reports with long
term follow-up on patients surviving metastatic breast cancer
and highlights the challenges of treating these patients and other
patients with metastatic disease. This case also demonstrates the
value of long term follow-up as emphasized by Codman and co-
workers [3,4]. He argued for his “end result idea” as a “common
sense idea” in that every hospital should follow every patient for a
long enough time to determine whether or not the treatment had
been successful and then to inquire, if not, why not. The goal was
to prevent similar failures in the future and determine what dif-
ferent courses of action might be better for patients in the future.
For this patient, given her status on presentation with metastatic
breast cancer lesions 5 years after mastectomy and chemotherapy
it was a reasonable course of action at that time to offer her pallia-
tive radiation. However, if we had been better able to predict the
outcome that she has had with very long term remission and pos-
sibly a cure we may have treated her differently. With an earlier
resection of the lesion we may have been able to salvage her arm
and hand or at least save her arm to her elbow.
In reviewing this case 31 years after initial diagnosis of breast
carcinoma we considered what might the prognostic indicators
that could have suggested a survival advantage for her been.While
her age on presentation and her biomarker proﬁle without the
availability of Herceptin would also make us think that she would
have a poor prognosis. We believe that the limited, skeletal only
location for her late recurrent disease could be a positive progno-
stic factor. There have been others who have argued that patients
with oligometastasis or limited lesions, such as hers, may repre-
sent a population who will go on to have more favorable outcomes
and would beneﬁt from more aggressive treatment with curative
intent [5–7] and there are reports that support this. Greenburg
et al. reports that at a mean of 15 years follow up 1.8% of patients
with metastatic breast cancer following combination chemother-
apy achieved complete responses into a disease free state. They also
described that the long term surviving group were of a younger
age, had a lower tumor burden but did not comment on metastatic
lesion sites [8]. Kobayashi et al. report a case series of 30 year expe-
riencewith aggressivemultidisciplinary treatment of breast cancer
with relapse free rate of 42% at 20 yearswithpatientswithmetasta-
sis to a single organ [9]. Ziaei et al. reported thatpatientswithbreast
cancer skeletal metastasis vs. other site metastasis has a slight sur-
vival beneﬁt [10]. Milano et al. reported 85 metastatic lesions in
40 breast cancer patients treated with Stereotactic Body Radiation
Treatment, achieving a 4-year overall survival of 59%. They found
that themost favorable prognostic factor for breast oligometastatic
patients was metastases only involving bone [11].
Breast cancer has a natural tendency to metastasize to bone.
70% of breast cancer patients develop bone metastasis [12]. The
molecular mechanism of tumor growth in bone has been elabo-
rated extensively and involves the receptive and supportive bone
microenvironment [13]. Much of the molecular data regarding
bonemetastasis highlights the invasive phenotype that is acquired
during this transition argues against any more positive outcome
with skeletal metastasis [14]. It has been hypothesized that that
in order to metastasize breast cancer must undergo an epithelial
to mesenchymal transition that increases its tropism to bone and
increases its aggressive nature [15]. Other phenotypic changes such
as expression of RANK andMMPmay affect the capacity of the cells
tometastasize and generate osteolytic lesions [16] andmay be spe-
ciﬁc to those tumors that are active in bone. The speciﬁc prognostic
beneﬁt of skeletal only metastasis may simply be that the lesions
have an unknown afﬁnity to bone which would cause debilitation
but not mortality the same way vital organ metastasis would.
We were able to complete immunohistochemistry on sam-
ples that had been saved in the department of pathology from
our patient’s initial amputation but not from her primary breast
excision which is one limitation on identifying the primary
tumor molecular proﬁle [17]. The tumor has an immunoproﬁle of
AR+/ER−/PR−/Her2/neu+ and morphology of apocrine carcinoma.
These tumors usually have distinct apocrine molecular signature
[18]. This type of tumor has recently been described through
screeningbreast carcinomawithARstaining [19]. It is expected that
the driving force for the tumor’s behavior will mainly be related
to the HER-2/neu overexpression and expected to be aggressive
[20]. Therefore, this tumor was expected to have worse outcome,
particularly with the lack of target therapy of trastuzumab on diag-
nosis. We did see signiﬁcant local aggressiveness but no further
metastasis despite signiﬁcant tumor burden. Thismay indicate that
other markers speciﬁc to metastastatic potential may be better for
predicting long term survival in patient’s such as ours.
4. Conclusion
Here,wepresent a case of a patientwith skeletal onlymetastatic
breast cancer and long term follow-up with extensive relapse free
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survival. This case reinforces the importance of giving patients
reasonable treatment options that give them the best chance at
survival and if they do, the best chance at a good functional result.
This case also demonstrates that there is still much that is left to
be learned about the phenotypes of metastatic breast cancer that
when treated with the appropriate therapies may result in a cure.
For some cases, more aggressive treatmentmay bemore beneﬁcial
than for others. However, at this point we have limited ability to
determinewhich fewpatientswill go on to survive theirmetastatic
cancer. It is our conclusion that at this time the patients who may
beneﬁt from further attention to the possibility of curative inten-
tion and more aggressive orthopedic intervention are those who
have had one or two lesions detected at greater than 3 years after
initial diagnosiswhen the primary site has been removed. This case
of long termfollowupremindsus that thereare in factpatientswith
signiﬁcant disease free periods from metastatic breast cancer that
deserve a unique treatment plan aimed at maintaining function.
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